Updated MST report - target of $3.68 a share, page-4

Hottod, he must have written this article on a monday morning lol. It truly doesnt make any sense.

Guys, reading through the good news today it struck me that this drug may be also powerful as a combination / concomitant medication. The more we learn about the characteristics of NNZ-2591 the more paths can be explored. The statement in regards to the effects (listed below) of the drug, would be a very strong candidate as a combination therapy drug. What do you guys think about that?

Both dose levels normalised all behavioral deficits
o Obesity eliminated by high dose
o Abnormally high insulin levels reduced to normal by high dose
o Abnormally low levels of circulating IGF-1 increased to normal by high dose
o Low dose partially improved obesity, insulin levels and circulating IGF-1 levels
o NNZ-2591 had no impact on normal mice - the consistent ability to treat impaired
animals successfully, but have no effects on normal animals (“state-dependent”
effects) is a valuable attribute of NNZ-2591